17 June 2025
We are happy to share this recent publication resulting from a collaborative effort between Vrije Universiteit Amsterdam (VU Amsterdam), Amsterdam UMC, and QVQ Holding BV. This study showcases the potential of functionalized single-domain antibodies (sdAbs) in biomedical research and therapeutic development.
By utilizing different fluorescent and luciferase-fused sdAbs, we were able to monitor the presence of higher-order clusters of CXCR4 on leukemic cells. These basal clusters could be disrupted by some small molecules, but also by our sdAb Q85 (VUN401). Interestingly, such disruption revealed that CXCR4 clusters actually drive oncogenic signaling and that targeting such clusters holds therapeutic potential.
At QVQ, we are excited about the expanding possibilities of sdAbs – not only for targeting CXCR4, but across a broad spectrum of targets. By offering a variety of functionalizations, we can reformat sdAbs for a large range of research, diagnostic, and therapeutic applications.
https://www.pnas.org/doi/10.1073/pnas.2424186122
